Jiangbo Pharmaceuticals (ehem. GNPH) - A0RNJB/JGBO
Jiangbo Pharmaceuticals, Inc. (JGBO.OB: 9.85 -1.50%) is trading up more than 30 percent from its May lows, but also remains a compelling value play. The Chinese pharmaceutical company reported fiscal 2009 net income of $8.9 million, or $0.44 per share, after an acquisition and restructuring charges, with $82.3 million, or $7.89 per share, in cash on its books. Meanwhile, the stock trades at just 5.5x earnings, assuming no growth during the upcoming year
Jiangbo’s Restructuring Efforts Appear to be Paying Off
By Justin • on June 8, 2009
Become a Member - It's FREE!
Comment Feed
Stumble it
Digg it
del.icio.us
Jiangbo Pharmaceuticals, Inc. (JGBO) posted record earnings of $8.9 million, or $0.44 per share, while retaining a robust balance sheet last quarter. Meanwhile, the pharmaceutical company reaffirmed operating income guidance of $40 to $43 million on revenues of $122 to $130 million amid a growing Chinese pharmaceuticals industry.
Jiangbo Pharmaceuticals, Inc. (JGBO.OB: 11.20 -4.68%), a U.S.-based company developing pharmaceutical products in China, began the year with a restructuring effort that could start paying big dividends. Revenues and net income figures were lower following restructuring charges, but a sharp increase in operating income and non-GAAP adjusted net income show promise.
Jiangbo’s Effective Restructuring
In January 2009, Jiangbo restructured its distribution and sales systems to concentrate on using 28 large independent regional distributors. The independent distributors agreed to take on higher direct marketing and sales expenses if they received lower unit prices for the company’s products. The predictable result is lower revenues, but less expenses and greater income.
Jiangbo’s discounts amounted to approximately 26% during their fiscal third quarter, which led to a drop in revenues. However, expenses fell 63.1% during the same period as advertising costs were shifted to the independent distributors. As a result, operating income increased 53.6% during the period, and the strategy appeared to pay off handsomely.
Despite the positive results, some investors remained concerned over Jiangbo’s net loss. However, a closer look reveals that these losses can be attributed to discontinued operations, a gain on trading securities, and amortization of debt. When these are taken out of the equation, the company reported non-GAAP adjusted net income of $10 million, or $0.97 per share.
Jiangbo’s Robust Balance Sheet
Jiangbo has also managed to keep a robust balance sheet, with $86.1 million in cash and working capital of $85.6 million. Meanwhile, current liabilities stood at just $27.4 million with convertible debt, net of $29.8 million discount, was $5.0 million. Finally, shareholder equity ended the quarter at $113.9 million, compared to $95.5 million as of June 30, 2008.
Meanwhile, strong cash flow generation of $41.4 million during the first nine months of fiscal 2009 will sustain its future working capital needs and successfully implement its growth strategies, which include the expansion of manufacturing facilities. This reduces the risks that the company will need to raise additional debt or equity capital in the near future.
Conclusions
In April 2009, the Chinese government unveiled its “Guideline of Deepening the Reform of Health Care System” – a blueprint for health care over the next decade. By 2020, the world’s most populated nation plans to have a basic health care system that can provide “safe, effective, convenient and affordable” health care services to urban and rural residents. The State Council also announced an investment of 850 billion Yuan (US$124 billion) to implement the health care reform plan in China.
In the end, Jiangbo’s restructuring plan appears to be effective in increasing operating income and should help increase revenue growth rates down the road. Meanwhile, a strong balance sheet and cash flow generation should help it preserve and increase shareholder value over the long-term. Combined with China’s rapidly growing pharmaceutical industry, this is a stock that investors may want to investigate closely over the coming months.
http://www.finanznachrichten.de/...rugs-trade-fair-in-tianjin-008.htm
Jiangbo Pharmaceuticals to Attend the 44th China New Drugs Trade Fair in Tianjin
Company to Launch Promotional Campaign for Laiyang Pear Cough Syrup
LAIYANG, China, June 18 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals Enterprises, Inc. (BULLETIN BOARD: JGBO) (the "Company", "Jiangbo"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that it will attend the China New Drugs Trade Fair from June 26 to 28, 2009 at Tianjin Binhai International Convention&Exhibition Center, and also plans to launch a new promotional campaign for its recently acquired Laiyang Pear Cough Syrup.
Jiangbo plans to promote its brand at the trade fair to increase the popularity of its Traditional Chinese Medicine (TCM) products. The Company will promote the portfolio of TCM products it acquired by purchasing Hongrui Pharmaceutical Company in early 2009 to its existing customers, and speak with new potential distributors.
...(weiter siehe LINK)
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=39142262
... "Crocker Coulson - about uplisting, he said they are working diligently on that and he exspects it to happen in the next 2 or 3 months." ...
3. You need to know what you're looking for. Like the aforementioned poison berry, picking the wrong attributes to look for in companies will lead you off the investing cliff. Ben Graham focused on the price-to-book ratio. Warren Buffett expanded this to price to earnings. Ken Fisher emphasized price to sales. Peter Lynch focused on price/earnings to growth. I use all four to evaluate stocks. Jiangbo Pharmaceuticals (JGBO.OB Quote) would be attractive on the measure of price to cash as well.
With a forward P/E between 2 and 3 and $85M in cash, Jiangbo is priced for bankruptcy at $113 million and it is nowhere close considering it has been growing both top and bottom lines at 50% annually.
Jiangbo Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
Laiyang, China, September 2, 2009 – Jiangbo Pharmaceuticals, Inc. (OTC Bulletin Board: JGBO) (the “Company”, “Jiangbo”), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that Ms. Elsa Sung, the Company’s CFO will present at the upcoming Rodman & Renshaw Annual Global Investment Conference to be held on September 9-11 at the New York Palace Hotel in New York City.
The date, time and location of Jiangbo Pharmaceuticals’ presentation at the conference are as follows:
Date: Wednesday, September 9, 2009
Time: 5:20 p.m. Eastern Time
Venue: Kennedy I Salon, 4th Floor
New York Palace Hotel
455 Madison Avenue
New York, NY 10022
Webcast: http://www.wsw.com/webcast/rrshq15/jgbo.ob
A replay of the presentation will be available for 90 days following the live presentation using the same link and will also be available on the Company’s website at http://www.jiangbopharma.com.
During the conference, the Company will be available to meet with analysts and portfolio managers. Interested parties and investors who wish to meet with Jiangbo Pharmaceuticals’ management may contact mwoodson@rodm.com or call (212) 430-1782. Participation in the Rodman and Renshaw Annual Global Investment Conference is by invitation only.
About Rodman & Renshaw, LLC
Rodman & Renshaw, LLC is a full service investment bank dedicated to providing investment banking services to companies that have significant capital needs, along with research and sales and trading services to investor clients. Rodman is a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets according to PrivateRaise a service of DealFlow Media Inc. and Sagient Research Systems, Inc.
About Jiangbo Pharmaceuticals, Inc.
Jiangbo Pharmaceuticals, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong province. Jiangbo is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. http://www.jiangbopharma.com
08.09.2009 14:06
Jiangbo Pharmaceuticals Reaffirms Guidance for Fiscal 2009
LAIYANG, China, Sept. 8 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (BULLETIN BOARD: JGBO) (the "Company", "Jiangbo"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today reaffirmed its previously announced guidance for fiscal year 2009. The Company expects to meet or exceed its goals of $111 to $116 million in revenue and operating income of $40 to $43 million for the fiscal year ending June 30, 2009.
"We plan to report our annual results for the fiscal year 2009 by the end of this month and are pleased to reaffirm we are on track to achieve our financial goals," said Mr. Wubo Cao, Chief Executive Officer of Jiangbo. "We continue to revamp the production lines which we acquired from Hongrui earlier this year. We expect this project to be completed in May 2010, when we should be able to begin mass production of other profitable TCM products. Thus, we continue to feel confident in maintaining a healthy growth rate over the long term."
...(weiter siehe LINK)
Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2009 Results
http://www.finanznachrichten.de/...d-fiscal-year-2009-results-008.htm
LAIYANG, China, Sept. 25 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc., (OTC Bulletin Board: JGBO; "Jiangbo" or the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that the Company will host a conference call at 9:00 a.m. Eastern Time on Tuesday, September 29, 2009 to discuss its fourth quarter and fiscal year 2009 financial results.
Conference Call
Mr. Wubo Cao, Chairman and CEO, and Ms. Elsa Sung, CFO, will host the conference call.
To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: (800) 688-0796. International callers can dial (617) 614-4070. The conference passcode is 442 269 29.
If you are unable to participate in the call at that time, a replay of the conference call will be available from Tuesday, September 29, 2009 at 11:00 a.m. Eastern Time for 14 days. To access the replay, please call (888) 286-8010. International callers can dial (617) 801-6888. The conference replay passcode is 829 987 55.
(weiter siehe LINK)
LAIYANG, China, Sept. 29 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (BULLETIN BOARD: JGBO) ("Jiangbo" or the "Company"), a pharmaceutical company with its principal operations in the People's Republic of China, today announced financial results for its fourth quarter and fiscal year ended June 30, 2009. The Company's annual report on Form 10-K was filed with the U.S. Securities Exchange Commission and is available on the Company's website.
Fourth Quarter FY 2009 Highlights:
-- Revenues increased 10.1% year-over-year to $31.2 million
-- Gross profit was $23.0 million, a 2.2% decrease from the comparable period in 2008
-- Operating income rose 74.6% year-over-year to $17.7 million
-- Net income grew 19.9% to $11.5 million, or $0.70 per fully diluted share
-- Non-GAAP adjusted net income was $12.1 million, or $0.81 per fully diluted share for the three months ended June 30, 2009, up 6.9% from non-GAAP adjusted net income of $11.3 million, or $0.94 per fully diluted share, for the quarter ended June 30, 2008
Fiscal Year 2009 Highlights:
-- Total revenue increased 17.9% year-over-year to $117.4 million
-- Gross profit increased 16. 1% to $89.5 million, as compared to the results in fiscal year 2008
-- Operating income rose 54.5% year-over-year to $49.8 million
-- Net income grew 28.6% to $28.9 million, as compared to the results in fiscal year 2008
-- Non-GAAP adjusted net income was $35.6 million, or $2.46 per fully diluted share in fiscal year of 2009, up 36.3% from non-GAAP adjusted net income of $26.1 million, or $2.60 per fully diluted share in fiscal year 2008
-- In July 2008, the Company received approval from China's State Food and Drug Administration ("SFDA") to start producing and distributing Radix Isatidis Dispersible Tablets, an herbal-based Traditional Chinese Medicine used for viral influenza
-- In January 2009, the Company acquired all of the assets of Shandong Hongrui Pharmaceutical Factory ("Hongrui") and obtained the legal rights to manufacture and distribute Hongrui's 22 Traditional Chinese Medicines
-- Beginning in January 2009, Jiangbo restructured its sales network to distribute products through 28 large regional distributors and increase efficiency
-- In April 2009, the Company changed its corporate name from Genesis Pharmaceuticals Enterprises, Inc. to "Jiangbo Pharmaceuticals, Inc." and its stock symbol from "GNPH" to "JGBO"
(...weiter siehe LINK)
Jiangbo Pharmaceuticals Announces Resignation of Chief Operating Officer
Date : 10/22/2009 @ 12:00PM
Source : PR Newswire
http://ih.advfn.com/...227713&article=40016954&symbol=NB^JGBO
Jiangbo Pharmaceuticals Announces Resignation of Chief Operating Officer
LAIYANG, China, Oct. 22 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (OTC:JGBO) (BULLETIN BOARD: JGBO) (the "Company" or "Jiangbo"), a pharmaceutical company with its principal operations in China, today announced the resignation of Mr. Haibo Xu, the Company's Chief Operating Officer ("COO"), effective October 20, 2009. Mr. Xu resigned for health reasons. The Company has initiated a search for a replacement candidate for COO. Mr. Xu will continue in his role as a member of the Company's Board of Directors.
Mr. Wubo Cao, the Company's Chief Executive Officer, said, "We would like to thank Mr. Xu for all of his contributions as Jiangbo's COO and we look forward to continuing to work with him as a valued board member who is committed to maximizing the Company's future growth and shareholder value."
About Jiangbo Pharmaceuticals, Inc.
Jiangbo Pharmaceuticals is engaged in the research, development, production, marketing and sales of pharmaceutical products in China. The Company's operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong Province. Jiangbo produces both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. For additional information, please visit the Company's website ( http://www.jiangbopharma.com/ ).
16.11.2009 14:02
Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010
LAIYANG, China, Nov. 16 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc., (OTC Bulletin Board: JGBO; "Jiangbo" or the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that the Company will host a conference call at 9:00 a.m. Eastern Time on Wednesday, November 18, 2009 to discuss financial results for its first quarter of fiscal year 2010.
Conference Call
Mr. Wubo Cao, Chairman and CEO, and Ms. Elsa Sung, CFO, will host the conference call.
To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: (800) 688 0796. International callers can dial (617) 614 4070. The conference passcode is 616 816 13.
If you are unable to participate in the call at that time, a replay of the conference call will be available from Wednesday, November 18, 2009 at 11:00 a.m. Eastern Time for 14 days. To access the replay, please call (888) 286 8010. International callers can dial (617) 801 6888. The conference replay passcode is 464 133 98.
Optionen
| Boardmail an "datschi" |
Wertpapier: JIANGBO PHARMACEUTICALS |
Posted by: 996 Date: Wednesday, January 06, 2010 11:17:18 AM
Maybe someone found out that Q2 brought great revenues, or that uplisting is around the corner, or that they have bought a fantastic new drug, or that one of the three drugs in the pipeline has been approved and is now ready for production, or institutional investors picking up...
So you see today's run could be caused by a lot of things